(8R,9S,10R,13S,14S)-10,13-Dimethyl-6-methylene-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17(10H,14H)-dione
| Title | Journal |
|---|---|
| Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. | Toxicology 20170615 |
| Better Together: Targeted Combination Therapies in Breast Cancer. | Seminars in oncology 20151201 |
| Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K Library. | Toxicological sciences : an official journal of the Society of Toxicology 20151001 |
| Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. | Journal of the National Cancer Institute 20151001 |
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | Toxicological sciences : an official journal of the Society of Toxicology 20150601 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. | The New England journal of medicine 20140710 |
| Novel aromatase inhibitors by structure-guided design. | Journal of medicinal chemistry 20121011 |
| Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. | Climacteric : the journal of the International Menopause Society 20121001 |
| Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. | Annals of oncology : official journal of the European Society for Medical Oncology 20121001 |
| mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. | Annals of oncology : official journal of the European Society for Medical Oncology 20121001 |
| The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. | The Journal of steroid biochemistry and molecular biology 20120901 |
| Stage-specific effects of androgens and estradiol-17beta on the development of late primary and early secondary ovarian follicles of coho salmon (Oncorhynchus kisutch) in vitro. | Biology of reproduction 20120901 |
| Aromatase inhibitors and mood disturbances. | Palliative & supportive care 20120901 |
| Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. | Radiology 20120901 |
| Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. | Anticancer research 20120901 |
| Exemestane for primary prevention of breast cancer in postmenopausal women. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120815 |
| Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). | Current medical research and opinion 20120801 |
| Psychotropic medication during endocrine treatment for breast cancer. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20120701 |
| Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. | Molecular biology reports 20120701 |
| Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. | Breast cancer research and treatment 20120701 |
| Whole-genome analysis informs breast cancer response to aromatase inhibition. | Nature 20120621 |
| Chemotherapy-resistant metastatic breast cancer. | Current treatment options in oncology 20120601 |
| Pharmacogenomics of third-generation aromatase inhibitors. | Expert opinion on pharmacotherapy 20120601 |
| The apples and oranges of cost-effectiveness. | Cleveland Clinic journal of medicine 20120601 |
| The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. | Future oncology (London, England) 20120601 |
| Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. | Psycho-oncology 20120501 |
| Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? | European journal of clinical pharmacology 20120501 |
| Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. | Analytical and bioanalytical chemistry 20120501 |
| Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). | Breast cancer research and treatment 20120501 |
| Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties. | Steroids 20120501 |
| Exemestane in the prevention setting. | Therapeutic advances in medical oncology 20120501 |
| Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). | Breast cancer research and treatment 20120401 |
| Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. | Annals of surgical oncology 20120401 |
| Aromatase inhibitors and musculoskeletal adverse events. | The Lancet. Oncology 20120401 |
| Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. | The Lancet. Oncology 20120401 |
| What is new in primary care? Best articles from the past year. | Obstetrics and gynecology 20120401 |
| Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. | Clinical breast cancer 20120401 |
| Complete response to exemestane in a patient with a desmoid tumor. | Future oncology (London, England) 20120401 |
| 6-Methyl-ideneandrost-4-ene-3,17-dione. | Acta crystallographica. Section E, Structure reports online 20120401 |
| Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320 |
| Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. | British journal of cancer 20120313 |
| Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120301 |
| Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120301 |
| Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. | Expert opinion on therapeutic targets 20120301 |
| Bone loss associated with prevention of breast cancer. | The Lancet. Oncology 20120301 |
| Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. | The Lancet. Oncology 20120301 |
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. | The New England journal of medicine 20120209 |
| Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. | JAMA 20120208 |
| Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. | Breast (Edinburgh, Scotland) 20120201 |
| Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. | Breast (Edinburgh, Scotland) 20120201 |
| Aromatase inhibitors and breast cancer prevention. | Expert opinion on pharmacotherapy 20120201 |
| Breast cancer chemoprevention. | Expert review of anticancer therapy 20120201 |
| Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. | Cancer 20120101 |
| Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. | European journal of cancer care 20120101 |
| Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. | The oncologist 20120101 |
| [Chemoprevention of breast cancer: exemestane ready to be tested in study setting]. | Nederlands tijdschrift voor geneeskunde 20120101 |
| Development, characterization, and in vitro evaluation of tamoxifen microemulsions. | Journal of drug delivery 20120101 |
| Major clinical research advances in gynecologic cancer in 2011. | Journal of gynecologic oncology 20120101 |
| Motion and flexibility in human cytochrome p450 aromatase. | PloS one 20120101 |
| Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. | Frontiers in pharmacology 20120101 |
| Targeting costimulatory molecules to improve antitumor immunity. | Journal of biomedicine & biotechnology 20120101 |
| Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature. | Case reports in medicine 20120101 |
| Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study. | Cancer management and research 20120101 |
| Exemestane for breast cancer prevention: a critical shift? | Cancer discovery 20120101 |
| An overview on dry eye treatment: approaches for cyclosporin a delivery. | TheScientificWorldJournal 20120101 |
| Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. | PloS one 20120101 |
| Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients. | Asian Pacific journal of cancer prevention : APJCP 20120101 |
| Carcinomatous pericarditis in 3 breast cancer patients with long-term survival. | Case reports in oncology 20120101 |
| Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. | Frontiers in pharmacology 20120101 |
| Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. | The breast journal 20120101 |
| BOLERO-2 - will this change practice in advanced breast cancer? | Breast cancer research : BCR 20120101 |
| [Gallbladder metastasis from breast carcinoma: a new case report]. | Revue medicale de Bruxelles 20120101 |
| Apoptosis and autophagy in breast cancer cells following exemestane treatment. | PloS one 20120101 |
| Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. | Current drug targets 20111201 |
| Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. | Journal of biomedical informatics 20111201 |
| Progress in endocrine approaches to the treatment and prevention of breast cancer. | Maturitas 20111201 |
| An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. | Advances in therapy 20111201 |
| Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. | Drug safety 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| The breast cancer chemoprevention debate. | Journal of the National Cancer Institute 20111116 |
| Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. | Breast cancer research and treatment 20111101 |
| Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. | Pharmacogenetics and genomics 20111101 |
| Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry. | The Journal of steroid biochemistry and molecular biology 20111101 |
| Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. | Clinical pharmacology and therapeutics 20111101 |
| ACP Journal Club. Exemestane prevented invasive breast cancer in postmenopausal women at moderately increased risk. | Annals of internal medicine 20111018 |
| Breast cancer medications and vision: effects of treatments for early-stage disease. | Current eye research 20111001 |
| Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer? | The American journal of gastroenterology 20111001 |
| Strategies for maximizing growth in puberty in children with short stature. | Pediatric clinics of North America 20111001 |
| Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110915 |
| Exemestane for breast-cancer prevention. | The New England journal of medicine 20110915 |
| Exemestane for breast-cancer prevention. | The New England journal of medicine 20110915 |
| Exemestane for breast-cancer prevention. | The New England journal of medicine 20110915 |
| Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: especially in patients treated with S-1 + trastuzumab. | Japanese journal of clinical oncology 20110901 |
| Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography. | Journal of chromatographic science 20110901 |
| Management of patients with metastatic breast cancer. | Advances in therapy 20110901 |
| Initialization of adjuvant hormonal treatment for breast cancer. | Advances in therapy 20110901 |
| Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. | Journal of pharmaceutical sciences 20110801 |
| Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. | Endocrine-related cancer 20110801 |
| Impaired reproduction in adult male, but not female, rats following juvenile treatment with the aromatase inhibitor, exemestane. | Birth defects research. Part B, Developmental and reproductive toxicology 20110801 |
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. | Clinical breast cancer 20110801 |
| Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. | American journal of clinical pathology 20110801 |
| Current role and safety profile of aromatase inhibitors in early breast cancer. | Expert review of anticancer therapy 20110801 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| Molecular effects of oestrogen deprivation in breast cancer. | Molecular and cellular endocrinology 20110704 |
| Overview of adjuvant trials of aromatase inhibitors in early breast cancer. | Steroids 20110701 |
| Binding features of steroidal and nonsteroidal inhibitors. | Steroids 20110701 |
| Examination of the use of Exemestane in patients with metastatic breast cancer. | Breast cancer (Tokyo, Japan) 20110701 |
| Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701 |
| Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. | Cell death & disease 20110701 |
| Exemestane for breast-cancer prevention in postmenopausal women. | The New England journal of medicine 20110623 |
| 'MAPping' the course of chemoprevention in breast cancer. | The New England journal of medicine 20110623 |
| Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610 |
| A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. | British journal of cancer 20110607 |
| The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. | Journal of cancer research and clinical oncology 20110601 |
| An 'omics' approach to determine the mechanisms of acquired aromatase inhibitor resistance. | Omics : a journal of integrative biology 20110601 |
| When to start an aromatase inhibitor: now or later? | Journal of surgical oncology 20110601 |
| Histologic and cytologic detection of endocrine and reproductive tract effects of exemestane in female rats treated for up to twenty-eight days. | Toxicologic pathology 20110601 |
| Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. | Journal of breast cancer 20110601 |
| Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. | British journal of cancer 20110510 |
| Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. | Journal of cancer research and clinical oncology 20110501 |
| Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. | The Journal of steroid biochemistry and molecular biology 20110501 |
| Drug safety evaluation of exemestane. | Expert opinion on drug safety 20110501 |
| Preventive therapy for breast cancer: a consensus statement. | The Lancet. Oncology 20110501 |
| Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. | Journal of the European Academy of Dermatology and Venereology : JEADV 20110501 |
| Estrogen and progesterone receptors in breast cancer. | Clinical advances in hematology & oncology : H&O 20110501 |
| Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? | Annals of the Royal College of Surgeons of England 20110501 |
| Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420 |
| A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20110401 |
| A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. | Breast cancer research and treatment 20110401 |
| Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. | Cancer science 20110401 |
| Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance? | British journal of cancer 20110329 |
| Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. | Journal of medicinal chemistry 20110324 |
| The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. | Annals of oncology : official journal of the European Society for Medical Oncology 20110301 |
| Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110301 |
| [Aromatase inhibitors and arthralgia]. | Magyar onkologia 20110301 |
| Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? | Critical reviews in oncology/hematology 20110201 |
| Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. | Breast cancer research and treatment 20110201 |
| Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. | Hormones & cancer 20110201 |
| Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. | Lancet (London, England) 20110122 |
| Time to TEAM: exemestane, or tamoxifen then exemestane? | Lancet (London, England) 20110122 |
| Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature. | American journal of therapeutics 20110101 |
| Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110101 |
| Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. | Breast cancer research and treatment 20110101 |
| Rheumatoid arthritis and aromatase inhibitors. | Joint, bone, spine : revue du rhumatisme 20110101 |
| In vitro cytochrome P450-mediated metabolism of exemestane. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| Role of estrogen in spermatogenesis in initial phase males of the three-spot wrasse (Halichoeres trimaculatus): effect of aromatase inhibitor on the testis. | Developmental dynamics : an official publication of the American Association of Anatomists 20110101 |
| Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? | Journal of biomedicine & biotechnology 20110101 |
| Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. | Sarcoma 20110101 |
| Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. | Breast cancer research : BCR 20110101 |
| Olive oil effectively mitigates ovariectomy-induced osteoporosis in rats. | BMC complementary and alternative medicine 20110101 |
| Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training. | Journal of aging research 20110101 |
| Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. | Breast cancer research : BCR 20110101 |
| Do aromatase inhibitors have adverse effects on cognitive function? | Breast cancer research : BCR 20110101 |
| Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. | BMC cancer 20110101 |
| Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. | Breast cancer research : BCR 20110101 |
| Income level and regional policies, underlying factors associated with unwarranted variations in conservative breast cancer surgery in Spain. | BMC cancer 20110101 |
| Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry. | Steroids 20110101 |
| Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. | Journal of Cancer 20110101 |
| Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. | OncoTargets and therapy 20110101 |
| Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. | Breast cancer research : BCR 20110101 |
| Malignancy-associated dyslipidemia. | The open cardiovascular medicine journal 20110101 |
| [Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial]. | Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20110101 |
| Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. | Reproductive biology and endocrinology : RB&E 20110101 |
| Aromatase inhibitors in post-menopausal endometriosis. | Reproductive biology and endocrinology : RB&E 20110101 |
| Aromatase inhibitors in men: effects and therapeutic options. | Reproductive biology and endocrinology : RB&E 20110101 |
| Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. | PloS one 20110101 |
| Promising molecular targeted therapies in breast cancer. | Indian journal of pharmacology 20110101 |
| Surviving metastatic breast cancer for 18 years: a case report and review of the literature. | The breast journal 20110101 |
| Breast Cancer Profile in a Group of Patients Followed up at the Radiation Therapy Unit of the Yaounde General Hospital, Cameroon. | Obstetrics and gynecology international 20110101 |
| Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. | BMC cancer 20110101 |
| Increased fracture rate in women with breast cancer: a review of the hidden risk. | BMC cancer 20110101 |
| Exemestane is effective for the chemoprevention of breast cancer. | CA: a cancer journal for clinicians 20110101 |
| Clinical relevance of 'withdrawal therapy' as a form of hormonal manipulation for breast cancer. | World journal of surgical oncology 20110101 |
| Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. | Advances and applications in bioinformatics and chemistry : AABC 20110101 |
| Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. | Genome medicine 20110101 |
| The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. | BMC cancer 20110101 |
| Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. | Journal of translational medicine 20110101 |
| Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. | Breast cancer : basic and clinical research 20110101 |
| Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. | Breast cancer research : BCR 20110101 |
| The immune response to tumors as a tool toward immunotherapy. | Clinical & developmental immunology 20110101 |
| Luminal-B breast cancer and novel therapeutic targets. | Breast cancer research : BCR 20110101 |
| Regression of late onset choroidal metastasis from a breast carcinoma with letrozole. | Case reports in ophthalmology 20110101 |
| The state of research into children with cancer across Europe: new policies for a new decade. | Ecancermedicalscience 20110101 |
| Endocrine-responsive breast cancer: a 28-year Odyssey. | Ecancermedicalscience 20110101 |
| Autophagy: friend or foe in breast cancer development, progression, and treatment. | International journal of breast cancer 20110101 |
| The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. | International journal of breast cancer 20110101 |
| [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. | Voprosy onkologii 20110101 |
| Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo. | Clinical sarcoma research 20110101 |
| Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. | Cancer metastasis reviews 20101201 |
| Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. | Gynecologic oncology 20101201 |
| Analysis of exemestane and 17β-hydroxyexemestane in human urine by gas chromatography/mass spectrometry: development and validation of a method using MO-TMS derivatives. | Rapid communications in mass spectrometry : RCM 20101130 |
| An alternative cyclodextrin based formulation for oral anticancer drug exemestane: In vitro and cell culture studies. | Journal of controlled release : official journal of the Controlled Release Society 20101120 |
| Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. | Critical reviews in oncology/hematology 20101101 |
| Cognitive changes associated with endocrine therapy for breast cancer. | Maturitas 20101101 |
| Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. | Breast cancer research and treatment 20101101 |
| Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. | European journal of cancer (Oxford, England : 1990) 20101101 |
| Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101 |
| [A successful case of the super elderly breast cancer patient treated with exemestane]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| Alternative oral exemestane formulation: improved dissolution and permeation. | International journal of pharmaceutics 20101015 |
| Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. | Pharmacogenetics and genomics 20101001 |
| A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. | Cancer 20100915 |
| Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. | British journal of cancer 20100907 |
| Exemestane-induced corneal epithelial changes. | Cutaneous and ocular toxicology 20100901 |
| Amelioration of sexual adverse effects in the early breast cancer patient. | Journal of cancer survivorship : research and practice 20100901 |
| Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. | The oncologist 20100901 |
| Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question? | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100901 |
| Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. | Anticancer research 20100901 |
| Death due to liver failure during endocrine therapy for premenopausal breast cancer. | Acta oncologica (Stockholm, Sweden) 20100801 |
| Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. | Breast cancer research and treatment 20100801 |
| Exemestane in postmenopausal women with early or advanced breast cancer: a review. | Expert opinion on pharmacotherapy 20100801 |
| Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study. | Clinical breast cancer 20100801 |
| Early recurrence risk: aromatase inhibitors versus tamoxifen. | Expert review of anticancer therapy 20100801 |
| Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. | British journal of cancer 20100727 |
| Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. | Maturitas 20100701 |
| Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100701 |
| Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. | American journal of clinical oncology 20100601 |
| Severe prolonged cholestatic hepatitis caused by exemestane. | Breast cancer research and treatment 20100601 |
| Aromatase inhibition in male breast cancer patients: biological and clinical implications. | Annals of oncology : official journal of the European Society for Medical Oncology 20100601 |
| Efficacy of exemestane, a new generation of aromatase inhibitor, on sex differentiation in a gonochoristic fish. | Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20100601 |
| Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. | Endocrine-related cancer 20100601 |
| Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. | Annals of oncology : official journal of the European Society for Medical Oncology 20100501 |
| Adjuvant aromatase inhibitor therapy: outcomes and safety. | Cancer treatment reviews 20100501 |
| Metastatic breast carcinoma presenting with profound hypocalcemia. | Southern medical journal 20100501 |
| Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. | The British journal of surgery 20100501 |
| Breast cancer in the personal genomics era. | Current genomics 20100501 |
| Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. | Breast cancer research and treatment 20100401 |
| Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry. | Analytical and bioanalytical chemistry 20100401 |
| 6beta-Methyl-B-norandrostenedione. | Acta crystallographica. Section C, Crystal structure communications 20100401 |
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. | British journal of cancer 20100316 |
| Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310 |
| Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. | Annals of oncology : official journal of the European Society for Medical Oncology 20100301 |
| Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. | Gynecologic oncology 20100301 |
| Computer-aided structure analysis of an epimerized dehydroepiandrosterone derivative and its biological effect in a model of reactive gliosis. | Steroids 20100301 |
| Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100301 |
| Differential diagnosis of lung nodules: breast cancer metastases and lung tuberculosis. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20100301 |
| Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding? | The Journal of steroid biochemistry and molecular biology 20100227 |
| Impact of aromatase inhibitors on bone health in breast cancer patients. | The Journal of steroid biochemistry and molecular biology 20100227 |
| Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. | The Journal of steroid biochemistry and molecular biology 20100227 |
| Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. | British journal of cancer 20100216 |
| Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100215 |
| Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. | Drug metabolism reviews 20100201 |
| Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. | Cancer treatment reviews 20100201 |
| Management of hot flashes in women with breast cancer. | Current oncology (Toronto, Ont.) 20100201 |
| Management of aromatase inhibitor-induced arthralgia. | Current oncology (Toronto, Ont.) 20100201 |
| Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. | British journal of cancer 20100119 |
| A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. | Breast cancer research and treatment 20100101 |
| A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. | BMC cancer 20100101 |
| Marginal growth increase, altered bone quality and polycystic ovaries in female prepubertal rats after treatment with the aromatase inhibitor exemestane. | Hormone research in paediatrics 20100101 |
| Bioequivalence of exemestane in post-menopausal females. | Arzneimittel-Forschung 20100101 |
| Impaired body weight and tail length gain and altered bone quality after treatment with the aromatase inhibitor exemestane in male rats. | Hormone research in paediatrics 20100101 |
| Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. | Breast cancer research : BCR 20100101 |
| Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report. | Journal of medical case reports 20100101 |
| Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report. | International archives of medicine 20100101 |
| Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report. | Diagnostic pathology 20100101 |
| Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. | Breast cancer research : BCR 20100101 |
| CTLA-4 blockade: therapeutic potential in cancer treatments. | OncoTargets and therapy 20100101 |
| Axillary sentinel lymph node biopsy after mastectomy: a case report. | World journal of surgical oncology 20100101 |
| Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. | Breast cancer research : BCR 20100101 |
| Clinical practice decisions in endocrine therapy. | Cancer investigation 20100101 |
| Network-based relating pharmacological and genomic spaces for drug target identification. | PloS one 20100101 |
| Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. | PloS one 20100101 |
| Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. | Journal of oncology 20100101 |
| The use of simvastatin with aromasin in an ovariectomized rat model: effects on the skeletal system. | Chang Gung medical journal 20100101 |
| Women and bone health: maximizing the benefits of aromatase inhibitor therapy. | Oncology 20100101 |
| Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors. | Oncology 20100101 |
| COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. | BMC cancer 20100101 |
| Hot flashes in breast cancer survivors and an association with calcium supplement use. | International journal of women's health 20100101 |
| Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study. | International journal of women's health 20100101 |
| Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations. | Breast cancer research : BCR 20100101 |
| FACE: the barefaced facts of AI potency. | Cancer management and research 20100101 |
| Inhibitory effect of flavonoids on mutant H-Rasp protein. | Bioinformation 20100101 |
| Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. | Oncology 20100101 |
| Pharmacoeconomic considerations in the treatment of breast cancer. | ClinicoEconomics and outcomes research : CEOR 20100101 |
| The role of funding and policies on innovation in cancer drug development. | Ecancermedicalscience 20100101 |
| Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer. | Indian journal of surgical oncology 20100101 |
| Development and validation of a stability indicating LC method for the assay and related substances determination of exemestane, an aromatase inhibitor. | Journal of pharmaceutical and biomedical analysis 20091205 |
| CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. | British journal of cancer 20091201 |
| Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. | Best practice & research. Clinical rheumatology 20091201 |
| [A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091201 |
| [A case of recurrent breast cancer responding to vinorelbine/trastuzumab combination therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091201 |
| Aromatase inhibitors to augment height: continued caution and study required. | Journal of clinical research in pediatric endocrinology 20091201 |
| Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. | Cancer science 20091101 |
| Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. | Cancer research 20091101 |
| Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. | British journal of cancer 20091020 |
| Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. | The Cochrane database of systematic reviews 20091007 |
| Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. | International journal of pharmaceutics 20091001 |
| Tamoxifen: the drug that came in from the cold. | British journal of cancer 20090915 |
| Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. | Breast cancer research and treatment 20090901 |
| Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). | AAPS PharmSciTech 20090901 |
| Strategies for maximizing growth in puberty in children with short stature. | Endocrinology and metabolism clinics of North America 20090901 |
| [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090901 |
| Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. | British journal of cancer 20090818 |
| Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. | Breast cancer research and treatment 20090801 |
| Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. | Breast cancer research and treatment 20090801 |
| Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. | Cancer biology & therapy 20090801 |
| Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors. | Clinical breast cancer 20090801 |
| Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. | Breast cancer research and treatment 20090701 |
| Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. | Annals of oncology : official journal of the European Society for Medical Oncology 20090701 |
| The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090701 |
| Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome. | The Annals of pharmacotherapy 20090701 |
| An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. | Current oncology (Toronto, Ont.) 20090701 |
| Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. | Current oncology (Toronto, Ont.) 20090701 |
| A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. | Journal of mass spectrometry : JMS 20090601 |
| The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. | Breast (Edinburgh, Scotland) 20090601 |
| History of aromatase: saga of an important biological mediator and therapeutic target. | Endocrine reviews 20090601 |
| Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. | Expert opinion on pharmacotherapy 20090601 |
| Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. | Breast cancer research and treatment 20090501 |
| A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. | Cancer 20090501 |
| [A case of recurrent breast cancer with liver metastasis responding to exemestane]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090501 |
| Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. | Annals of oncology : official journal of the European Society for Medical Oncology 20090401 |
| Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20090401 |
| Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? | European journal of cancer (Oxford, England : 1990) 20090301 |
| Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. | British journal of cancer 20090210 |
| Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. | Breast cancer research and treatment 20090201 |
| Treating elderly patients with hormone sensitive breast cancer: what do the data show? | Cancer treatment reviews 20090201 |
| Aromatase inhibitors and bone health. | Current opinion in obstetrics & gynecology 20090201 |
| Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. | Annals of the New York Academy of Sciences 20090201 |
| Targeting aromatase and estrogen signaling in human non-small cell lung cancer. | Annals of the New York Academy of Sciences 20090201 |
| A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. | Clinical breast cancer 20090201 |
| Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. | British journal of cancer 20090113 |
| Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20090101 |
| Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. | Annals of oncology : official journal of the European Society for Medical Oncology 20090101 |
| Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Breast cancer in young women and its impact on reproductive function. | Human reproduction update 20090101 |
| Current indications for post-mastectomy radiation. | International seminars in surgical oncology : ISSO 20090101 |
| Diagnosis and treatment of early breast cancer, including locally advanced disease--summary of NICE guidance. | BMJ (Clinical research ed.) 20090101 |
| Successful pregnancy after breast cancer therapy: dream or reality? | International seminars in surgical oncology : ISSO 20090101 |
| Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. | Breast cancer (Tokyo, Japan) 20090101 |
| Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. | Journal of experimental & clinical cancer research : CR 20090101 |
| Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. | Breast cancer research : BCR 20090101 |
| A review of the use of exemestane in early breast cancer. | Therapeutics and clinical risk management 20090101 |
| Exemestane: a review of its use in postmenopausal women with breast cancer. | Drugs 20090101 |
| Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. | Menopause (New York, N.Y.) 20090101 |
| In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. | BMC cancer 20090101 |
| Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. | Breast cancer research : BCR 20090101 |
| The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. | BMC medical genomics 20090101 |
| [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma]. | Voprosy onkologii 20090101 |
| Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. | Breast cancer research : BCR 20090101 |
| Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review. | Therapeutics and clinical risk management 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. | Journal of hematology & oncology 20090101 |
| Update on the use of aromatase inhibitors in early-stage breast cancer. | Breast cancer research : BCR 20090101 |
| Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. | World journal of surgical oncology 20090101 |
| Antiproliferative effect of exemestane in lung cancer cells. | Molecular cancer 20090101 |
| Drug-induced hematologic syndromes. | Advances in hematology 20090101 |
| Are current drug development programmes realising the full potential of new agents? The scenario. | Breast cancer research : BCR 20090101 |
| Foundation clinical trials. | Breast cancer research : BCR 20090101 |
| Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report. | Tumori 20090101 |
| Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. | International journal of general medicine 20090101 |
| The evolving role of zoledronic acid in early breast cancer. | OncoTargets and therapy 20090101 |
| Aromatase inhibitor strategies in metastatic breast cancer. | International journal of women's health 20090101 |
| Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. | Breast cancer : basic and clinical research 20090101 |
| Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. | Breast cancer : basic and clinical research 20090101 |
| The evolution of treatment for early breast cancer: what's next? | Ecancermedicalscience 20090101 |
| Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. | British journal of cancer 20081209 |
| Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. | Breast cancer research and treatment 20081201 |
| Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. | Breast cancer research and treatment 20081201 |
| The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. | European journal of internal medicine 20081201 |
| The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. | Clinical breast cancer 20081201 |
| Are all aromatase inhibitors alike? | Breast cancer research and treatment 20081201 |
| Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. | Clinical interventions in aging 20081201 |
| Exemestane in early breast cancer: a review. | Therapeutics and clinical risk management 20081201 |
| Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). | Breast cancer research and treatment 20081101 |
| Aromatase inhibitors in the management of early breast cancer. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20081101 |
| Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. | Pharmaceutical research 20081101 |
| Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081020 |
| Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. | International journal of clinical oncology 20081001 |
| Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. | Breast cancer research and treatment 20080901 |
| Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. | Breast cancer research and treatment 20080901 |
| Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids. | Biological chemistry 20080901 |
| Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20080901 |
| Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. | Drugs of today (Barcelona, Spain : 1998) 20080901 |
| tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. | British journal of cancer 20080819 |
| Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. | British journal of cancer 20080805 |
| Resistance to chemotherapy: new treatments and novel insights into an old problem. | British journal of cancer 20080805 |
| Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. | Surgical oncology 20080801 |
| Synthesis of exemestane labelled with (13)C. | Steroids 20080801 |
| Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence? | Breast (Edinburgh, Scotland) 20080801 |
| Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? | The oncologist 20080801 |
| Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. | Clinical breast cancer 20080801 |
| Aromatase inhibition versus placebo. | Clinical breast cancer 20080801 |
| The endocrine prevention of breast cancer. | Best practice & research. Clinical endocrinology & metabolism 20080801 |
| Reduced expression of cyclooxygenase-2 in primary breast cancer. | Journal of the National Cancer Institute 20080716 |
| Exemestane: the dawn of a new era in breast cancer treatment. | Journal of cancer research and clinical oncology 20080701 |
| Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080701 |
| Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? | Annals of oncology : official journal of the European Society for Medical Oncology 20080701 |
| The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. | European journal of oncology nursing : the official journal of European Oncology Nursing Society 20080701 |
| Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. | The Journal of steroid biochemistry and molecular biology 20080701 |
| Experience with exemestane in the treatment of early and advanced breast cancer. | Expert opinion on drug metabolism & toxicology 20080701 |
| Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. | Cancer research 20080615 |
| Exemestane loaded self-microemulsifying drug delivery system (SMEDDS): development and optimization. | AAPS PharmSciTech 20080601 |
| Planar scintimammography and SPECT in neoadjuvant chemo or hormonotherapy response evaluation in locally advanced primary breast cancer. | International journal of oncology 20080601 |
| Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women. | Mini reviews in medicinal chemistry 20080601 |
| Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials? | Cancer investigation 20080601 |
| [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?]. | Magyar onkologia 20080601 |
| Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. | British journal of cancer 20080506 |
| Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. | Annals of oncology : official journal of the European Society for Medical Oncology 20080501 |
| CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. | Drug metabolism and disposition: the biological fate of chemicals 20080501 |
| Targeting breast cancer with hormonal treatment options. | The Nurse practitioner 20080501 |
| Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420 |
| Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. | Cancer treatment reviews 20080401 |
| Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401 |
| Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. | Breast (Edinburgh, Scotland) 20080401 |
| Aromatase inhibitors in early breast-cancer treatment: The story so far. | Breast (Edinburgh, Scotland) 20080401 |
| The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. | Cancer research 20080401 |
| Neoadjuvant endocrine therapy for breast cancer: past, present and future. | Anti-cancer drugs 20080401 |
| Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080310 |
| Update: a 62-year-old woman with a new diagnosis of breast cancer. | JAMA 20080305 |
| NSAIDs and breast cancer: a possible prevention and treatment strategy. | International journal of clinical practice 20080301 |
| Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings. | Annals of surgical oncology 20080301 |
| Aromatase inhibitors for breast cancer: different structures, same effects? | Endocrine-related cancer 20080301 |
| Menopausal symptoms and adjuvant therapy-associated adverse events. | Endocrine-related cancer 20080301 |
| Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward. | Anti-cancer drugs 20080301 |
| Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? | Anti-cancer drugs 20080301 |
| [The effect of hormone therapy on cognitive function in patients with breast cancer]. | Nederlands tijdschrift voor geneeskunde 20080301 |
| Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. | Cancer 20080201 |
| [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080201 |
| Exemestane: an alternative treatment option in early breast cancer. Foreward. | Anti-cancer drugs 20080201 |
| Intergroup Exemestane Study mature analysis: overall survival data. | Anti-cancer drugs 20080201 |
| Statistical analysis in cancer clinical trials. | Anti-cancer drugs 20080201 |
| European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. | Breast (Edinburgh, Scotland) 20080201 |
| Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. | Clinical breast cancer 20080201 |
| Long-term safety of aromatase inhibitors in the treatment of breast cancer. | Therapeutics and clinical risk management 20080201 |
| The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. | Annals of oncology : official journal of the European Society for Medical Oncology 20080101 |
| Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. | Journal of cancer research and clinical oncology 20080101 |
| Aromatase inhibitors: past, present and future in breast cancer therapy. | Medical oncology (Northwood, London, England) 20080101 |
| Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). | Breast cancer research and treatment 20080101 |
| To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision? | Expert review of anticancer therapy 20080101 |
| Chemoprevention of breast cancer. | Breast cancer (Tokyo, Japan) 20080101 |
| Aromatase inhibitors: from bench to bedside and back. | Breast cancer (Tokyo, Japan) 20080101 |
| Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. | Current oncology (Toronto, Ont.) 20080101 |
| Cancer treatment-related bone loss: a review and synthesis of the literature. | Current oncology (Toronto, Ont.) 20080101 |
| The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. | Breast (Edinburgh, Scotland) 20080101 |
| Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. | BMC cancer 20080101 |
| Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. | Breast cancer research : BCR 20080101 |
| Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101 |
| [Adjuvant treatment of operable breast cancer]. | Anales de medicina interna (Madrid, Spain : 1984) 20080101 |
| [Exemestane in the treatment of breast carcinoma: recent findings]. | Tumori 20080101 |
| Cancer and fertility preservation: fertility preservation in breast cancer patients. | Breast cancer research : BCR 20080101 |
| Evaluation of the quality and accuracy of information regarding aromatase inhibitors available on the internet. | The breast journal 20080101 |
| New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. | BMC cell biology 20080101 |
| Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. | Journal of experimental & clinical cancer research : CR 20080101 |
| Exacerbation of diabetes related to exemestane treatment. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Exemestane-induced subclinical hypothyroidism : a case report. | Clinical drug investigation 20080101 |
| Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. | Breast cancer (Tokyo, Japan) 20080101 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | Human reproduction update 20080101 |
| Neoplastic effects of exemestane in premenopausal breast cancer model. | Neoplasma 20080101 |
| Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. | Breast cancer research : BCR 20080101 |
| Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. | Breast cancer research : BCR 20080101 |
| Integration of endocrine therapy with targeted agents. | Breast cancer research : BCR 20080101 |
| Approaches towards expression profiling the response to treatment. | Breast cancer research : BCR 20080101 |
| Cancer care in Singapore. | Biomedical imaging and intervention journal 20080101 |
| Response of cutaneous metastases from breast cancer to capecitabine. | Clinical medicine. Oncology 20080101 |
| Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching. | Journal of cancer research and clinical oncology 20071201 |
| Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors. | Cancer treatment reviews 20071201 |
| The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. | International journal of clinical practice 20071201 |
| Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. | Breast cancer research and treatment 20071201 |
| Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. | Breast (Edinburgh, Scotland) 20071201 |
| Management of arthralgias associated with aromatase inhibitor therapy. | Current oncology (Toronto, Ont.) 20071201 |
| Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. | Current oncology (Toronto, Ont.) 20071201 |
| Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada. | Current oncology (Toronto, Ont.) 20071201 |
| National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. | Clinical breast cancer 20071201 |
| Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. | Clinical breast cancer 20071201 |
| Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20071101 |
| Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. | Critical reviews in oncology/hematology 20071101 |
| The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. | Current opinion in oncology 20071101 |
| Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. | Molecular cancer therapeutics 20071101 |
| Progression of endocrine therapies for breast cancer: where are we headed? | Expert review of anticancer therapy 20071101 |
| Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. | European journal of cancer (Oxford, England : 1990) 20071101 |
| Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020 |
| Letrozole in advanced breast cancer: the PO25 trial. | Breast cancer research and treatment 20071001 |
| Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. | Breast (Edinburgh, Scotland) 20071001 |
| Aromatase inhibitor and bone. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20071001 |
| The discovery and mechanism of action of letrozole. | Breast cancer research and treatment 20071001 |
| Letrozole in the neoadjuvant setting: the P024 trial. | Breast cancer research and treatment 20071001 |
| Letrozole in the extended adjuvant setting: MA.17. | Breast cancer research and treatment 20071001 |
| Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. | Breast cancer research and treatment 20071001 |
| A decade of letrozole: FACE. | Breast cancer research and treatment 20071001 |
| Safety of aromatase inhibitors in the adjuvant setting. | Breast cancer research and treatment 20071001 |
| The patient experience. | Breast cancer research and treatment 20071001 |
| [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer]. | Ugeskrift for laeger 20070910 |
| Reducing the risk of early recurrence in hormone-responsive breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| The molecular genetics of breast cancer and targeted therapy. | Biologics : targets & therapy 20070901 |
| Nonsurgical treatment of male infertility: specific and empiric therapy. | Biologics : targets & therapy 20070901 |
| Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. | British journal of cancer 20070820 |
| An evaluation of the OECD 308 water/sediment systems for investigating the biodegradation of pharmaceuticals. | Environmental science & technology 20070815 |
| An alpha-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen. | British journal of cancer 20070806 |
| Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. | Breast (Edinburgh, Scotland) 20070801 |
| Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. | Cancer 20070801 |
| Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. | Clinical therapeutics 20070801 |
| Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. | Minerva ginecologica 20070801 |
| Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. | Cancer 20070715 |
| Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. | Breast cancer research and treatment 20070701 |
| Hormonal therapies for early breast cancer: systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20070701 |
| Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. | Breast (Edinburgh, Scotland) 20070601 |
| Aromatase inhibitors in the treatment of severe endometriosis. | Obstetrics and gynecology 20070601 |
| The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. | Current oncology (Toronto, Ont.) 20070601 |
| Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer. | Current opinion in molecular therapeutics 20070601 |
| Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. | Clinical journal of oncology nursing 20070601 |
| Exemestane or tamoxifen? | Lancet (London, England) 20070512 |
| Exemestane or tamoxifen? | Lancet (London, England) 20070512 |
| Exemestane or tamoxifen? | Lancet (London, England) 20070512 |
| Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. | Breast cancer research and treatment 20070501 |
| Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition. | Cancer letters 20070418 |
| [Clinical study of aromatase inhibitors in advanced breast cancer]. | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20070418 |
| Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. | Bone 20070401 |
| Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma. | Planta medica 20070401 |
| [Advancement in endocrine therapy for breast cancer]. | Ai zheng = Aizheng = Chinese journal of cancer 20070401 |
| Male breast cancer with mandibular metastasis. A case report. | Minerva stomatologica 20070401 |
| Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. | Expert review of pharmacoeconomics & outcomes research 20070401 |
| Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. | Breast cancer research and treatment 20070301 |
| Aromatase inhibitors: a safety comparison. | Expert opinion on drug safety 20070301 |
| Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. | Cancer investigation 20070301 |
| Cancer: some reasons to be hopeful. | Lancet (London, England) 20070217 |
| Switching to aromatase inhibitors in early breast cancer. | Lancet (London, England) 20070217 |
| Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. | Lancet (London, England) 20070217 |
| Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. | Molecular endocrinology (Baltimore, Md.) 20070201 |
| Optimal treatment strategies in hormone-responsive early breast cancer: the role of aromatase inhibitors. | Onkologie 20070201 |
| Optimising bone health in survivors of breast cancer. | The Lancet. Oncology 20070201 |
| Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. | The Lancet. Oncology 20070201 |
| The prevention and management of distant metastases in women with breast cancer. | Cancer investigation 20070201 |
| Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. | The Cochrane database of systematic reviews 20070124 |
| Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. | Journal of the National Cancer Institute 20070117 |
| 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. | International journal of cancer 20070115 |
| Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. | Bone 20070101 |
| Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. | Steroids 20070101 |
| Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. | The breast journal 20070101 |
| [A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070101 |
| [Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070101 |
| Tamoxifen-associated vasculitis in a breast cancer patient. | World journal of surgical oncology 20070101 |
| Estrogen deprivation for breast cancer prevention. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101 |
| The ethics of CYP2D6 testing for patients considering tamoxifen. | Breast cancer research : BCR 20070101 |
| Neoadjuvant use of endocrine therapy in breast cancer. | The breast journal 20070101 |
| Exemestane: a milestone against breast cancer. | Journal of postgraduate medicine 20070101 |
| Quality of life issues in relation to the aromatase inhibitor. | The Journal of steroid biochemistry and molecular biology 20070101 |
| New experimental models for aromatase inhibitor resistance. | The Journal of steroid biochemistry and molecular biology 20070101 |
| Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. | Breast cancer research : BCR 20070101 |
| Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. | Anticancer research 20070101 |
| Amping up estrogen receptors in breast cancer. | Breast cancer research : BCR 20070101 |
| Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20070101 |
| Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. | Breast cancer research : BCR 20070101 |
| Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males. | Journal of the International Society of Sports Nutrition 20070101 |
| [Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer]. | Voprosy onkologii 20070101 |
| Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. | Breast cancer research : BCR 20070101 |
| Robotic-assisted laparoscopic cytoreductive surgery for lobular carcinoma of the breast metastatic to the ovaries. | Journal of minimally invasive gynecology 20070101 |
| [Neoadjuvant endocrine therapy for locally advanced breast cancer]. | La Clinica terapeutica 20070101 |
| Adjuvant endocrine therapy for premenopausal women with early breast cancer. | Breast cancer research : BCR 20070101 |
| Arzoxifene: the evidence for its development in the management of breast cancer. | Core evidence 20070101 |
| [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole]. | Nederlands tijdschrift voor geneeskunde 20061230 |
| What do we know about the mechanisms of aromatase inhibitor resistance? | The Journal of steroid biochemistry and molecular biology 20061201 |
| Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. | Seminars in oncology 20061201 |
| Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. | Expert opinion on pharmacotherapy 20061201 |
| Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. | Current medical research and opinion 20061201 |
| Aromatase inhibitors and bone health in women with breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120 |
| Metastatic breast cancer: an updating. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20061101 |
| Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. | European journal of cancer (Oxford, England : 1990) 20061101 |
| Optimal sequence of hormonotherapy in advanced breast cancer. | Current opinion in oncology 20061101 |
| Safety of adjuvant aromatase inhibitor therapy. | Cancer treatment reviews 20061101 |
| A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. | European journal of cancer (Oxford, England : 1990) 20061101 |
| Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. | Cancer research 20061101 |
| Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. | Journal of the National Comprehensive Cancer Network : JNCCN 20061101 |
| Effects of adjuvant aromatase inhibitor therapy on lipid profiles. | Expert review of anticancer therapy 20061101 |
| Aromatase inhibitors: structural features and biochemical characterization. | Annals of the New York Academy of Sciences 20061101 |
| Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. | Breast (Edinburgh, Scotland) 20061001 |
| Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women. | Breast cancer research and treatment 20061001 |
| Update on the use of aromatase inhibitors in breast cancer. | Expert opinion on pharmacotherapy 20061001 |
| Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? | British journal of cancer 20060918 |
| [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060901 |
| The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. | Reviews on recent clinical trials 20060901 |
| Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. | Current medical research and opinion 20060801 |
| Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. | Current medical research and opinion 20060801 |
| The evolving role of exemestane in the management of breast cancer. | British journal of hospital medicine (London, England : 2005) 20060801 |
| Aromatase inhibitors and bone loss. | Oncology (Williston Park, N.Y.) 20060801 |
| Leuprolide acetate plus aromatase inhibition for male breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720 |
| Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. | British journal of cancer 20060717 |
| Can switching treatments improve breast-cancer outcome? | The Lancet. Oncology 20060701 |
| [Derivatives of exemestane--synthesis and evaluation of aromatase inhibition]. | Die Pharmazie 20060701 |
| Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. | British journal of cancer 20060619 |
| Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. | Breast (Edinburgh, Scotland) 20060601 |
| Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. | Breast (Edinburgh, Scotland) 20060601 |
| Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. | Journal of cancer research and clinical oncology 20060601 |
| Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data. | Journal of surgical oncology 20060601 |
| Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601 |
| Management of choroidal metastases from breast carcinomas using aromatase inhibitors. | Current opinion in ophthalmology 20060601 |
| Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. | Clinical breast cancer 20060601 |
| Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors. | International journal of clinical practice 20060601 |
| Effects of third-generation aromatase inhibitors on bone. | European journal of cancer (Oxford, England : 1990) 20060501 |
| Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060501 |
| Primary hormone treatment in postmenopausal women with breast cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060501 |
| Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons. | British journal of pharmacology 20060401 |
| A 62-year-old woman with a new diagnosis of breast cancer. | JAMA 20060322 |
| Aromatase inhibitors and breast cancer. | Minerva endocrinologica 20060301 |
| [The evolving role of endocrine therapy for breast cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20060301 |
| Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? | British journal of cancer 20060227 |
| Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060220 |
| COX inhibitors and breast cancer. | British journal of cancer 20060213 |
| Neoadjuvant endocrine therapy in breast cancer. | Breast (Edinburgh, Scotland) 20060201 |
| Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. | Annals of oncology : official journal of the European Society for Medical Oncology 20060201 |
| Adjuvant endocrine therapy for postmenopausal women with early breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060201 |
| Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060201 |
| Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting. | Breast (Edinburgh, Scotland) 20060201 |
| Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. | Breast (Edinburgh, Scotland) 20060201 |
| Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. | Clinical breast cancer 20060201 |
| Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. | British journal of cancer 20060116 |
| Estrogen receptors as therapeutic targets in breast cancer. | Current topics in medicinal chemistry 20060101 |
| Does survival increase in metastatic breast cancer with recently available anticancer drugs? | Oncology research 20060101 |
| Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). | Tumori 20060101 |
| Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20060101 |
| Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report. | European journal of gynaecological oncology 20060101 |
| Efficacy and tolerability of high dose 'ethinylestradiol' in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. | World journal of surgical oncology 20060101 |
| Cardiovascular safety profiles of aromatase inhibitors : a comparative review. | Drug safety 20060101 |
| Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update. | International seminars in surgical oncology : ISSO 20060101 |
| Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| Bone safety of aromatase inhibitors versus tamoxifen. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101 |
| [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer]. | Tumori 20060101 |
| Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. | Breast cancer research : BCR 20060101 |
| A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids. | Rapid communications in mass spectrometry : RCM 20060101 |
| Appraising adjuvant aromatase inhibitor therapy. | The oncologist 20060101 |
| Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. | The oncologist 20060101 |
| Adjuvant therapy for patients who have node-positive breast cancer. | Advances in surgery 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| [Current status of breast cancer chemoprevention]. | Revista da Associacao Medica Brasileira (1992) 20060101 |
| Bone loss with exemestane: Is the jury still out? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220 |
| Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051215 |
| Human aromatase: gene resequencing and functional genomics. | Cancer research 20051201 |
| [Advance and current status of exemestane and androstadienes in the treatment of breast cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051201 |
| Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051115 |
| New developments in the treatment of postmenopausal breast cancer. | Trends in endocrinology and metabolism: TEM 20051101 |
| The use of aromatase inhibitors in adjuvant therapy for early breast cancer. | Cancer chemotherapy and pharmacology 20051101 |
| Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. | Clinical therapeutics 20051101 |
| New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. | Cancer 20051001 |
| A review of exemestane in the management of breast cancer. | Expert opinion on pharmacotherapy 20051001 |
| Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. | Clinical breast cancer 20051001 |
| Current directions for COX-2 inhibition in breast cancer. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001 |
| Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001 |
| Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20051001 |
| Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. | Anti-cancer drugs 20050901 |
| Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer. | The journal of the British Menopause Society 20050901 |
| The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. | Breast cancer research and treatment 20050901 |
| Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050901 |
| Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. | Current opinion in obstetrics & gynecology 20050801 |
| Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801 |
| Aromatase inhibitors and bone loss: risks in perspective. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801 |
| New approaches to reverse resistance to hormonal therapy in human breast cancer. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050801 |
| The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. | European journal of cancer (Oxford, England : 1990) 20050801 |
| Role of aromatase inhibitors in breast cancer. | British journal of cancer 20050801 |
| Potential use of COX-2-aromatase inhibitor combinations in breast cancer. | British journal of cancer 20050801 |
| Bone loss and the aromatase inhibitors. | British journal of cancer 20050801 |
| The effects of aromatase inhibitors on lipids and thrombosis. | British journal of cancer 20050801 |
| Sequencing of aromatase inhibitors. | British journal of cancer 20050801 |
| Use of goserelin in the treatment of breast cancer. | Expert review of anticancer therapy 20050801 |
| The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. | Clinical breast cancer 20050801 |
| [Aromatase inhibitors in the treatment of breast cancer: current status and some problems]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20050801 |
| Lipid adjustment in the analysis of environmental contaminants and human health risks. | Environmental health perspectives 20050701 |
| Chemoprevention in breast cancer. | Clinical advances in hematology & oncology : H&O 20050701 |
| A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. | Cancer treatment reviews 20050601 |
| Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen. | Prescrire international 20050601 |
| Skeletal health in postmenopausal survivors of early breast cancer. | International journal of cancer 20050510 |
| Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. | British journal of cancer 20050509 |
| Aromatase inhibitors in the treatment of breast cancer. | Endocrine reviews 20050501 |
| Safety of exemestane in the Intergroup Exemestane Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050501 |
| The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. | Cancer research 20050501 |
| Aromatase inhibitors for therapy of advanced breast cancer. | The Journal of steroid biochemistry and molecular biology 20050501 |
| Aromatase and comparative response to its inhibitors in two types of endometrial cancer. | The Journal of steroid biochemistry and molecular biology 20050501 |
| Aromatase inhibitors: cellular and molecular effects. | The Journal of steroid biochemistry and molecular biology 20050501 |
| Aromatase inhibition: translation into a successful therapeutic approach. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050415 |
| ATAC trial update. | Lancet (London, England) 20050401 |
| Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. | Clinical breast cancer 20050401 |
| Anastrozole. | Drugs of today (Barcelona, Spain : 1998) 20050401 |
| [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells]. | MMW Fortschritte der Medizin 20050310 |
| Innovations in antineoplastic therapy. | The Nursing clinics of North America 20050301 |
| A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. | British journal of clinical pharmacology 20050301 |
| [Effective reduction of elevated tumor markers by exemestane--a 12-year follow-up of a case of bone metastatic breast cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20050301 |
| Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050215 |
| Endocrine treatment options for advanced breast cancer--the role of fulvestrant. | European journal of cancer (Oxford, England : 1990) 20050201 |
| The choice of systemic adjuvant therapy in receptor-positive early breast cancer. | European journal of cancer (Oxford, England : 1990) 20050201 |
| Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? | Cancer treatment reviews 20050201 |
| Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050201 |
| [A patient with metastatic breast cancer associated with retention of pleural effusion with no response to both CMF and exemestane, whose life was saved by high-dose toremifene]. | Gan to kagaku ryoho. Cancer & chemotherapy 20050201 |
| Are aromatase inhibitors superior to antiestrogens? | The Journal of steroid biochemistry and molecular biology 20050201 |
| Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050115 |
| Exemestane for breast cancer prevention: a feasible strategy? | Clinical cancer research : an official journal of the American Association for Cancer Research 20050115 |
| Prevention of hormone-related cancers: breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050110 |
| Aromatase 2004, Edinburgh, UK, 6-8 September 2004. | Breast cancer research : BCR 20050101 |
| Clinical trial update: National Cancer Institute of Canada. | Breast cancer research : BCR 20050101 |
| Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women. | Breast cancer research : BCR 20050101 |
| Aromatase expression in ovarian epithelial cancers. | The Journal of steroid biochemistry and molecular biology 20050101 |
| Optimizing the treatment of metastatic breast cancer. | Breast cancer research and treatment 20050101 |
| Aromatase inhibitors in the treatment of early and advanced breast cancer. | Acta oncologica (Stockholm, Sweden) 20050101 |
| [Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]. | Voprosy onkologii 20050101 |
| Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? | Breast cancer research : BCR 20050101 |
| Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. | Oncology 20050101 |
| Early stopping of clinical trials. | Breast cancer research : BCR 20050101 |
| The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. | Reproductive biology and endocrinology : RB&E 20050101 |
| Life following aromatase inhibitors--where now for endocrine sequencing? | Breast cancer research and treatment 20050101 |
| Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. | Breast cancer research : BCR 20050101 |
| Clinical trial update: International Breast Cancer Study Group. | Breast cancer research : BCR 20050101 |
| Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. | MedGenMed : Medscape general medicine 20050101 |
| Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. | Oncology 20050101 |
| Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. | Breast cancer research : BCR 20050101 |
| Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. | Breast disease 20050101 |
| State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments. | German medical science : GMS e-journal 20050101 |
| Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. | Annals of oncology : official journal of the European Society for Medical Oncology 20041201 |
| [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. | Bulletin du cancer 20041201 |
| Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. | Clinical journal of oncology nursing 20041201 |
| Aromatase inhibitors and breast cancer: time for a change? | International journal of clinical practice 20041201 |
| Aromatase inhibitors in advanced breast cancer. | Seminars in oncology 20041201 |
| Aromatase inhibitors in early breast cancer therapy. | Seminars in oncology 20041201 |
| Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit. | Seminars in oncology 20041201 |
| [Aromatase inhibitors in adjuvant setting in breast cancer]. | Bulletin du cancer 20041201 |
| Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. | The Journal of biological chemistry 20041112 |
| Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041101 |
| [Anastrozole-resistant breast cancer responsive to exemestane--a case report]. | Gan to kagaku ryoho. Cancer & chemotherapy 20041101 |
| Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy. | Bulletin of experimental biology and medicine 20041101 |
| Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer? | Nature clinical practice. Oncology 20041101 |
| Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. | Cancer treatment reviews 20041001 |
| The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. | Cancer 20041001 |
| [A case of aged advanced breast cancer with multiple lung and pleural metastases responding to exemestane monotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20041001 |
| Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. | Current opinion in investigational drugs (London, England : 2000) 20041001 |
| Exemestane following tamoxifen in postmenopausal women with primary breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040915 |
| Current developments in hormonal therapy of breast cancer. | Clinical breast cancer 20040901 |
| Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? | Clinical breast cancer 20040901 |
| Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040901 |
| A review of adjuvant hormonal therapy in breast cancer. | Endocrine-related cancer 20040901 |
| Beating breast cancer. | Nursing standard (Royal College of Nursing (Great Britain) : 1987) 20040801 |
| Role of aromatase inhibitors in the treatment of breast cancer. | Clinical therapeutics 20040801 |
| Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040715 |
| Adjuvant treatment of breast cancer with exemestane. | The New England journal of medicine 20040701 |
| Adjuvant treatment of breast cancer with exemestane. | The New England journal of medicine 20040701 |
| Adjuvant treatment of breast cancer with exemestane. | The New England journal of medicine 20040701 |
| The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. | Cancer chemotherapy and pharmacology 20040601 |
| A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. | Toxicology 20040601 |
| Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? | Cancer treatment reviews 20040601 |
| Aromatase inhibitors in breast cancer. | Endocrine-related cancer 20040601 |
| [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20040601 |
| [Aromatase inhibitors in the adjuvant therapy of breast carcinomas]. | Therapeutische Umschau. Revue therapeutique 20040601 |
| Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? | British journal of cancer 20040504 |
| Tamoxifen shuffle. | Health news (Waltham, Mass.) 20040501 |
| [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]. | Bulletin du cancer 20040501 |
| [Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]. | Bulletin du cancer 20040501 |
| Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. | Journal of the American Geriatrics Society 20040401 |
| The role of COX-2 inhibition in breast cancer treatment and prevention. | Seminars in oncology 20040401 |
| Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040315 |
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. | The New England journal of medicine 20040311 |
| New stars in the sky of treatment for early breast cancer. | The New England journal of medicine 20040311 |
| Aromatase inhibitors for chemoprevention. | Best practice & research. Clinical endocrinology & metabolism 20040301 |
| Aromatase inhibitors that regulate estrogen target tissues selectively? | Bone 20040301 |
| The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. | Bone 20040301 |
| Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. | British journal of cancer 20040301 |
| Fulvestrant and the sequential endocrine cascade for advanced breast cancer. | British journal of cancer 20040301 |
| Metastatic breast cancer response after Exemestane withdrawal: a case report. | Breast (Edinburgh, Scotland) 20040201 |
| The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. | Annals of oncology : official journal of the European Society for Medical Oncology 20040201 |
| Exemestane and aromatase inhibitors in the management of advanced breast cancer. | Expert opinion on pharmacotherapy 20040201 |
| [Controversies in endocrine therapy for breast cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040201 |
| Aromatase inhibitors: new endocrine treatment of breast cancer. | Seminars in reproductive medicine 20040201 |
| First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? | British journal of cancer 20040112 |
| Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. | Breast cancer research : BCR 20040101 |
| 8th Nottingham International Breast Cancer Conference, Nottingham, UK, 16-19 September 2003. | Breast cancer research : BCR 20040101 |
| Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Prevention strategies with aromatase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Neoadjuvant endocrine therapy as a drug development strategy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| [Neoadjuvant endocrine therapy for breast cancer: an overview]. | Bulletin du cancer 20040101 |
| Aromatase inhibitors for breast cancer in postmenopausal women. | The oncologist 20040101 |
| Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. | European journal of gynaecological oncology 20040101 |
| Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. | Anti-cancer drugs 20040101 |
| Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004. | Breast cancer research : BCR 20040101 |
| Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. | Breast cancer research : BCR 20040101 |
| Tamoxifen--what next? | The oncologist 20040101 |
| Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. | Annals of oncology : official journal of the European Society for Medical Oncology 20040101 |
| Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. | Cancer control : journal of the Moffitt Cancer Center 20040101 |
| Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. | Breast cancer research : BCR 20040101 |
| [New results of endocrine therapy of breast cancer (the role of Aromasin)]. | Voprosy onkologii 20040101 |
| Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. | The Journal of clinical endocrinology and metabolism 20031201 |
| Clinical trials update: Medical management of advanced breast cancer. | Cancer nursing 20031201 |
| Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20031101 |
| Aromatase inhibitors in breast cancer therapy. | Clinical breast cancer 20031101 |
| [Pharmacological and clinical profile of exemestane (Aromasin), a novel irreversible aromatase inhibitor]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031001 |
| The pharmacology of letrozole. | The Journal of steroid biochemistry and molecular biology 20031001 |
| An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. | The Canadian journal of urology 20031001 |
| Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20030901 |
| Exemestane seems to stimulate tumour growth in men with prostate carcinoma. | European journal of cancer (Oxford, England : 1990) 20030901 |
| [Clinical trial on exemestane in the treatment of postmenopausal women with advanced breast cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20030901 |
| The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Aromatase inhibitors as adjuvant therapies in patients with breast cancer. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings. | The Journal of steroid biochemistry and molecular biology 20030901 |
| An integrated view of aromatase and its inhibition. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. | The Journal of steroid biochemistry and molecular biology 20030901 |
| Breast cancer prevention--clinical trials strategies involving aromatase inhibitors. | The Journal of steroid biochemistry and molecular biology 20030901 |
| The current status of aromatase inhibitors in the management of breast cancer. | The Surgical clinics of North America 20030801 |
| A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. | American journal of clinical oncology 20030801 |
| Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. | American journal of clinical oncology 20030801 |
| Emerging role of aromatase inhibitors in the adjuvant setting. | American journal of clinical oncology 20030801 |
| Should aromatase inhibitors replace tamoxifen? | Drug and therapeutics bulletin 20030801 |
| Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. | Seminars in oncology 20030801 |
| Pharmacokinetics of third-generation aromatase inhibitors. | Seminars in oncology 20030801 |
| The role of aromatase inhibitors in the treatment of metastatic breast cancer. | Seminars in oncology 20030801 |
| Aromatase inhibitors in early breast cancer treatment. | Seminars in oncology 20030801 |
| Challenges in the endocrine management of breast cancer. | Breast (Edinburgh, Scotland) 20030801 |
| Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? | The Journal of steroid biochemistry and molecular biology 20030701 |
| Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? | International journal of oncology 20030501 |
| Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. | Oncology (Williston Park, N.Y.) 20030501 |
| The role of aromatase inhibitors in early breast cancer. | Current treatment options in oncology 20030401 |
| Update on the current use of hormonals as therapy in advanced breast cancer. | Anti-cancer drugs 20030401 |
| Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. | Expert review of anticancer therapy 20030401 |
| [Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases]. | Zhonghua yi xue za zhi 20030210 |
| Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030101 |
| Clinical differences among the aromatase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030101 |
| A roundtable discussion of aromatase inhibitors as therapy for breast cancer. | The breast journal 20030101 |
| 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003. | Breast cancer research : BCR 20030101 |
| Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. | The oncologist 20030101 |
| Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. | Anticancer research 20030101 |
| [Perspectives for the hormonal therapy of breast cancer]. | Magyar onkologia 20030101 |
| Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. | Breast cancer research and treatment 20030101 |
| Exemestane: treatment of breast cancer with selective inactivation of aromatase. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021115 |
| An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. | Cancer 20021101 |
| Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. | European journal of cancer (Oxford, England : 1990) 20021101 |
| New generation aromatase inhibitors--from the advanced to the adjuvant setting. | Breast cancer research and treatment 20021001 |
| Sequencing of endocrine therapies in breast cancer--integration of recent data. | Breast cancer research and treatment 20021001 |
| The evolving role of aromatase inhibitors in breast cancer. | International journal of clinical oncology 20021001 |
| The role of aromatase inactivators in the treatment of breast cancer. | International journal of clinical oncology 20020801 |
| Exemestane, a new steroidal aromatase inhibitor of clinical relevance. | Biochimica et biophysica acta 20020718 |
| [Phase I single-dose administration study of exemestane in postmenopausal women]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020701 |
| [Phase I multiple-dose administration study of exemestane in postmenopausal women]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020701 |
| [Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020701 |
| [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020701 |
| Overview of the pharmacology of the aromatase inactivator exemestane. | Breast cancer research and treatment 20020701 |
| Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review). | International journal of oncology 20020601 |
| Letrozole for the management of breast cancer. | Expert review of anticancer therapy 20020601 |
| Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. | Expert review of anticancer therapy 20020601 |
| Recent advances in aromatase inhibitor therapy for breast cancer. | Seminars in oncology 20020601 |
| New breast cancer drugs expand treatment options. | Harvard women's health watch 20020401 |
| Antiaromatase agents: evolving role in adjuvant therapy. | Clinical breast cancer 20020401 |
| [The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile]. | Minerva ginecologica 20020401 |
| Aromatase inhibitors in breast cancer therapy. | Expert review of anticancer therapy 20020401 |
| Aromatase inhibitors in breast cancer. | Trends in endocrinology and metabolism: TEM 20020301 |
| Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. | British journal of cancer 20020201 |
| [Aromatase inhibitors of the 3rd generation. What can the 'pill against breast cancer' really do?]. | MMW Fortschritte der Medizin 20020131 |
| Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. | PharmacoEconomics 20020101 |
| Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. | Drugs 20020101 |
| Anti-aromatase agents in the treatment and prevention of breast cancer. | Cancer control : journal of the Moffitt Cancer Center 20020101 |
| Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. | Cancer control : journal of the Moffitt Cancer Center 20020101 |
| Estrogen as therapy for breast cancer. | Breast cancer research : BCR 20020101 |
| The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. | Clinical therapeutics 20020101 |
| Evolving uses of hormonal agents for breast cancer therapy. | Clinical therapeutics 20020101 |
| Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. | Clinical therapeutics 20020101 |
| The role of aromasin in the hormonal therapy of breast cancer. | Pathology oncology research : POR 20020101 |
| McCune-Albright syndrome--the German experience. | Journal of pediatric endocrinology & metabolism : JPEM 20020101 |
| Current role of endocrine therapy in the management of breast cancer. | Breast cancer (Tokyo, Japan) 20020101 |
| High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. | Surgery 20011201 |
| The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention. | Annals of the New York Academy of Sciences 20011201 |
| Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. | The Journal of steroid biochemistry and molecular biology 20011201 |
| Local endocrine effects of aromatase inhibitors within the breast. | The Journal of steroid biochemistry and molecular biology 20011201 |
| A summary of second-line randomized studies of aromatase inhibitors. | The Journal of steroid biochemistry and molecular biology 20011201 |
| Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. | The Journal of steroid biochemistry and molecular biology 20011201 |
| Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? | The Journal of steroid biochemistry and molecular biology 20011201 |
| The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Are differences in the available aromatase inhibitors and inactivators significant? | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Preliminary data from ongoing adjuvant aromatase inhibitor trials. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Future use of selective estrogen receptor modulators and aromatase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Aromatase inhibitors and inactivators in breast cancer. | BMJ (Clinical research ed.) 20011020 |
| Role of anti-aromatase agents in postmenopausal advanced breast cancer. | Cancer chemotherapy and pharmacology 20011001 |
| Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010901 |
| Nonsteroidal and steroidal aromatase inhibitors in breast cancer. | Oncology (Williston Park, N.Y.) 20010801 |
| Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure. | Prescrire international 20010801 |
| Endocrine therapy in the treatment of metastatic breast cancer. | Seminars in oncology 20010601 |
| Exemestane: a review of its clinical efficacy and safety. | Breast (Edinburgh, Scotland) 20010601 |
| Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. | Oncology (Williston Park, N.Y.) 20010501 |
| Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. | Oncology (Williston Park, N.Y.) 20010501 |
| Steroidal side effects of exemestane. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401 |
| Metastatic breast cancer: understanding current management options. | Oncology nursing forum 20010401 |
| Importance of local aromatase activity in hormone-dependent breast cancer: a review. | Breast (Edinburgh, Scotland) 20010401 |
| Aromatase inhibitors in the treatment and prevention of breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201 |
| Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. | Cancer 20010201 |
| Breast cancer chemoprevention: beyond tamoxifen. | Breast cancer research : BCR 20010101 |
| Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits. | Reproductive toxicology (Elmsford, N.Y.) 20010101 |
| Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000. | Breast cancer research : BCR 20010101 |
| [Modern approaches to hormone therapy of breast cancer as a reflection of pathogenesis of the disease]. | Voprosy onkologii 20010101 |
| Aromatase, aromatase inhibitors, and breast cancer. | American journal of therapeutics 20010101 |
| Third-generation aromatase inhibitors in the treatment of advanced breast cancer. | Breast cancer (Tokyo, Japan) 20010101 |
| Aromatase and aromatase inhibitors. | Breast cancer (Tokyo, Japan) 20010101 |
| Aromatase inhibitors. | Current medical research and opinion 20010101 |
| Glomerular hyperfiltration in diabetes mellitus. | Diabetic medicine : a journal of the British Diabetic Association 19850701 |